BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Following tislelizumabs initial approval in classical Hodgkins lymphoma (cHL) by the NMPA in December 2019, this is the second indication approved for tislelizumab, and the first in a solid tumor indication. The supplemental new drug application (sNDA) was previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.

At BeiGene, we strive to bring innovative, impactful, and quality treatments to patients around the globe. This is our third NDA approval in the past five months for our internally developed products, a tremendous accomplishment for a young biotechnology company like BeiGene and validation of the teams hard work, commented John V. Oyler, Chairman, Co-Founder, and CEO of BeiGene. Our strategy for tislelizumab has always been to pursue a broad label and serve patients who are battling different types of cancer. With tislelizumabs first solid tumor approval, we are even more excited about the outlook for this immunotherapy than ever.

Patients with advanced UC have limited treatment options, so we are delighted to have tislelizumab, a new immuno-oncology treatment available to them. Supported by encouraging efficacy and safety results from the trial, including an objective response rate of 24.8%, we believe tislelizumab will bring significant benefits to this patient population, commented Dingwei Ye, M.D., Ph.D., Professor and Vice President of the Fudan University Shanghai Cancer Center.

We are thrilled about todays approval of tislelizumab in UC, which was made possible by dedicated clinicians who participated in the trial, patients who entrusted our clinical trial with their treatment, and the team at BeiGene. We hope our broad development program for tislelizumab, which encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkins lymphoma and UC, will continue its momentum and benefit more patients, said Wendy Yan, Senior Vice President and Global Head of Regulatory Affairs atBeiGene.

The NMPA approval is based on the clinical results from a single-arm, multi-center pivotal Phase 2 trial of tislelizumab in patients in China and South Korea with PD-L1+ locally advanced or metastatic UC who were previously treated with platinum-containing chemotherapy (NCT04004221). Among patients who were evaluable for response, with a minimum follow-up of 12 months and a median follow-up of 14 months, the objective response rate (ORR) as assessed by the independent review committee (IRC) per RECIST v1.1 criteria was 24.8%, and the complete response (CR) rate was 9.9%.

The safety data for tislelizumab included in the label is based on 934 patients treated with tislelizumab monotherapy from four clinical trials, including the aforementioned pivotal Phase 2 trial in patients with UC. Most common ( 10%) adverse reactions included rash, fatigue, and increased alanine aminotransferase. Grade 3 or higher adverse reactions occurring in 1% of patients included: increased gammaglutamyl transferase, anemia, increased aspartate aminotransferase, increased alanine aminotransferase, pneumonitis, severe skin reactions, and hypokalemia.

Like other immune checkpoint inhibitors, tislelizumab could cause immune-related adverse reactions that mainly include pneumonitis, diarrhea and colitis, hepatitis, endocrinopathies (hypothyroidism, hyperthyroidism and thyroiditis, adrenocortical insufficiency, hyperglycemia and type 1 diabetes mellitus), and skin adverse reactions. Occasionally, nephritis, pancreatitis, myocarditis, myositis, and other immune-related adverse reactions were also reported.

The recommended dose of tislelizumab is 200 mg administered as an intravenous infusion every three weeks until disease progression or intolerable toxicity.

Tislelizumab is a biologic product approved under the Marketing Authorization Holder (MAH) pilot program in China and is being manufactured by Boehringer Ingelheim at its facility in Shanghai as the commercial supplier. Established in 1885, Boehringer Ingelheim has over 35 years of biologic manufacturing experience, and with more than 3,600 employees and a global network, its contract biopharmaceutical manufacturing business has helped to bring more than 30 molecules to the market globally.

About Urothelial Carcinoma

Urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer,1 accounting for more than 90 percent of all bladder cancers.2 Bladder cancer is the 10th most common cancer worldwide with approximately 550,000 new cases in 2018.3 In China, bladder cancer is the 8th most common cancer in men with approximately 62,000 new cases in 2019.4 Although UC is most common in the bladder, it can occur in other parts of the urinary system.

About Tislelizumab

Tislelizumab (BGB-A317) is a humanized IgG4 antiPD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGenes immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for patients with classical Hodgkins lymphoma who received at least two prior therapies and for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Tislelizumab is being manufactured by Boehringer Ingelheim at its facility in Shanghai as the commercial supplier. Following required qualifications and approvals, BeiGene plans to provide additional commercial supply through its commercial-scale biologics manufacturing facility in Guangzhou, which completed its initial phase of construction in September 2019.

Currently, 15 registration-enabling clinical trials of tislelizumab are being conducted in China and globally, including 11 Phase 3 trials and four pivotal Phase 2 trials.

Tislelizumab is not approved for use outside China.

About the Tislelizumab Clinical Program

Clinical trials of tislelizumab include:

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Srl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit http://www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGenes plans and expectations for the commercialization of tislelizumab, the potential implications of clinical data for patients, and BeiGenes further advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Companys clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

1 American Cancer Society https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html

2 ASCO cancer.net https://www.cancer.net/cancer-types/bladder-cancer/introduction

3 Global Cancer Observatory https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf

4 Zheng, et al. China Journal of Oncology, 2019,41(1): 19-28.

Here is the original post:
China National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic...

Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The US$283m market-cap company announced a latest loss of -US$75.6m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on PBYIs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for PBYIs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Puma Biotechnology

PBYI is bordering on breakeven, according to the 8 Biotechs analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$11m in 2022. So, PBYI is predicted to breakeven approximately 2 years from now. What rate will PBYI have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 62%, which is extremely buoyant. If this rate turns out to be too aggressive, PBYI may become profitable much later than analysts predict.

NasdaqGS:PBYI Past and Future Earnings April 8th 2020

Underlying developments driving PBYIs growth isnt the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with PBYI is its debt-to-equity ratio of over 2x. Typically, debt shouldnt exceed 40% of your equity, which in PBYIs case, it has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are too many aspects of PBYI to cover in one brief article, but the key fundamentals for the company can all be found in one place PBYIs company page on Simply Wall St. Ive also put together a list of key aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more from the original source:
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? - Yahoo Finance

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.15 to be very precise. The Stock rose vividly during the last session to $31.4 after opening rate of $29.55 while the lowest price it went was recorded $29.55 before closing at $30.08.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.47% during the 52-week period from high price, and 167.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.56 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 147.71%, having the revenues showcasing 83.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.41B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 24.32, with a change in the price was noted +19.25. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +161.76% for the period of last 100 days, recording 780,574 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 25.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.58%. In the last 20 days, the companys Stochastic %K was 27.22% and its Stochastic %D was recorded 25.85%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 147.71%. The shares increased approximately by 1.57% in the 7-day charts and went up by 6.21% in the period of the last 30 days. Common stock shares were driven by 83.45% during last recorded quarter.

Go here to see the original:
Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months - The InvestChronicle

The COVID-19 pandemic highlights the need for an overhaul of the government's regulatory system for animalbiotechnology products,the Biotechnology Innovation Organization said in a letter to President Donald Trump Tuesday.

The Food and Drug Administrations current approach to regulating all applications of this technology as a new animal drug should be replaced with a new model that more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment, BIO President and CEO Jim Greenwood said. BIO called on USDA and FDA to sign a Memorandum of Understanding within 30 days, a move endorsed by Ag Secretary Sonny Perdue in February.

Animal biotech researchers have been critical of FDAs approach, saying it is cumbersome and hinders the development of new technology.

In its one-page letter, BIO said COVID-19 highlights the interconnectedness of human, animal, and environmental health. While it would not have prevented the current pandemic, animal biotechnology holds enormous potential to safeguard society from future zoonotic diseases that frequently exact high economic and health costs, and to develop human therapeutics relevant to the current outbreak.

Zoonotic diseases are those that jump from animals to humans, as is suspected in the case of the novel coronavirus. In an opinion piece posted on the Agri-Pulse website Tuesday, BIO Executive Vice President for Food and Agriculture Dana OBrien said, As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

For more news, go to http://www.Agri-Pulse.com.

View post:
FDA, USDA need to reach agreement on animal biotech, BIO says - Agri-Pulse

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the companys response, operationally and scientifically.

Dear Generex Shareholders,

The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain times the health and well-being of our Generex family, including our employees, shareholders, investors and partners is paramount. For the well-being of all of our stakeholders, we are committed to following the precautions of health advisors and adhering to suggestions, advice, and laws set up by local municipalities, cities, states, and the federal government to stop this pandemic that has disrupted the world. Generex Biotechnology remains dedicated to safeguarding your investment in GNBT as we continue working towards positive outcomes into the future through our strategic initiatives and development programs, including our previously announced efforts to develop a vaccine for the SARS-CoV-2 virus.

We want to take this time to update shareholders on the steps we are taking to efficiently manage the businesses of Generex and our subsidiaries through these challenging times. We are virtually fully operational with all our business management teams and their employees through video conference and are committed to following through with our short, mid and long-term goals and plans to add value for our shareholders.

As reported Generex has jumped into the vaccine race with its Ii-Key-COVID-19 Complete Vaccine, which is designed to activate both the cellular (CD4 and CD8 T cells) and humoral (antibody) immune responses. As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.

Generex has also partnered with EpiVax, a leader in computational vaccinology, that has developed algorithms to identify specific amino acid peptide sequences or epitopes that are predicted to activate the various cellular components of the immune system including CD4 T Cells, CD8 T Cells, and B Cells that produce antibodies. An additional advantage of their vaccinology algorithms is their ability to dehumanize peptide sequences to minimize autoimmune reactions. EpiVax has identified a series of epitopes of the SARS-CoV-2 viral proteins that may be used to produce a vaccine. Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.

To advance our vaccine development efforts, the team at Generex has been proactive in reaching out to a number of countries, and we have had productive conversations with several government officials, Ministries of Health, and other key influencers to describe our technology, our clinical strategy, potential manufacturing partners, and our rapid path to vaccination for their populations. Generex has also met and had discussions with U.S. government agencies to provide them with details of our Ii-Key peptide vaccine technology, and we are in discussions with the decision makers for federal funding and partnership. It has been a slow process, but we believe that vaccines are now getting more government attention as local, state, and federal officials recognize the severity of this pandemic and the likelihood that the virus will return next year.

Generex has identified a clinical research organization, regulatory consultants, and clinical research sites to conduct our trials, and we are working with our contract manufacturing partners for AE37 to produce our Ii-Key-SARS-CoV-2 peptide vaccine for human clinical trials and population vaccination initiatives. We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.

Story continues

Generex is highly confident in our rapid vaccine development program and in our plans to scale the manufacturing of Ii-Key- SARS-CoV-2 peptide vaccines to conduct not only the clinical trials required to meet the approval standards of global regulatory authorities, but to meet government expectations for mass population vaccination.

In conclusion, while the COVID-19 pandemic is surely a fast evolving situation with multiple layers of complexity, we believe market conditions should ultimately favor long-term minded, value oriented, and fundamental investors. Generex has many subsidiaries and many assets, from its FDA-cleared wound care product Excellegen, to our development products in inflammatory bowel diseases, diabetes, infectious disease, and cancer, to our pending operations in Arizona, with the ultimate vision of building a HMO with, in our opinion, unprecedented benefit packages through our own products, devices, and ancillary services. Based on all these efforts and assets, it is my belief that Generex has the staying power to thrive and bring value to our shareholders. Rest assured, Generex is well equipped to navigate the current environment as we remain focused on our core competencies and businesses while positioning our high-value assets for the future.

In the immediate days ahead, we will continue working to solidify the development path and government partnerships to complete our Ii-Key-SARS-CoV-2 Complete Vaccine program so that we can make a difference not only for Generex, our employees, and our shareholders, but for the world. Finally, we thank you all for your continued support as we navigate through this difficult period together, and please everyone, stay safe, be well and take care of your families and friends.

Sincerely,Joe MoscatoCEO

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Follow this link:
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic - Yahoo Finance

Orlando, Fla., April 07, 2020 (GLOBE NEWSWIRE) -- Mission Biotech, an educational, immersive 3D game featuring many hours of gameplay and challenges, is being offered free to educators as well as students interested in learning how scientists search and test for clues to identify a virus during a pandemic outbreak.

The game presents an immersive storyline that teaches middle-school students and above the laboratory protocols and the real-world concepts, procedures, and tools of the biotechnology field. This free download is being announced in response to the COVID-19 outbreak to support teachers and students as they adapt to new ways of learning during this challenging time.

Mission Biotech is a great way to encourage careers in biotechnology, said Randy Brown, Applied Research Associates, Inc. (ARA) vice president and division manager of Virtual Heroes, which developed the game. This game offers students a way to play, learn, and become a real hero of tomorrow.

In the game, users play as part of a virtual team trying to stop the spread of dangerous pathogens, and the clock is ticking. The player is a new member of the National Laboratory for Biotechnology and Bioinformatics. On this, their first mission, players need to learn laboratory protocol while also understanding the basic scientific concepts behind biotechnology processes.

Gameplay includes discovering and using high-tech, fully-functional laboratory equipment, and features more than 50 different inventory items and a wide range of clues to find and use. Players can collect up to 20 accomplishment badges and unlock mini-games; these games also reinforce the scientific concepts behind DNA extraction and Polymerase Chain Reaction (PCR) processes. These processes are being used in real life today to test for pathogens such as the novel coronavirus. Reference materials are also available for educators and learners on the download site.

With schools closing across the nation, we want to do our part to leverage any educational opportunities we can, Brown said. This software is an opportunity for students everywhere to engage in immersive biotech learning content while gaining a real-world understanding of the challenges facing scientists today.

Mission Biotech was funded by a grant from the National Science Foundation to the University of Florida, and developed on the Epic Games Unreal Engine by the Virtual Heroes Division of Applied Research Associates, Inc. This educational outreach is being coordinated between ARA, the Serious Play Conference, and the National Center for Simulation, all in Orlando, Florida.

Visit https://youtu.be/exMqEG-qOf8 for a game overview and then go to http://www.virtualheroes.biz/MissionBiotech to download Mission Biotech and start learning today.

Continue reading here:
Free First-Person Adventure Game Allows Students to Learn Biotechnology Processes As They Hunt for the Virus during a Pandemic - GlobeNewswire

Dublin, April 08, 2020 (GLOBE NEWSWIRE) -- The "Global Dental Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Dental Partnering 2010 to 2020 provides the full collection of Dental disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Dental disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dental deals. It also presents financial deal terms values for Dental deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Dental dealmaking trends.

In addition, a comprehensive appendix is provided with each report of all Dental partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Dental partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Dental technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/u1um83

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the rest here:
Dental Partnering Deals Collection 2010-2020: Provides the Full Collection of Dental Disease Deals Signed Between the World's Leading Pharmaceutical...

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

Vir Biotechnology, Inc., belongs to Healthcaresector and Biotechnologyindustry. The companys Market capitalization is $4.07B with the total Outstanding Shares of 264. On 06-04-2020 (Monday),VIRstock construct a change of 26.55 in a total of its share price and finished its trading at 36.7.

Profitability Ratios (ROE, ROA, ROI):

Looking into the profitability ratios of VIR stock, an investor will find its ROE, ROA, ROI standing at 0%, 0% and -41.9%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investments cost.

Earnings per Share Details of Vir Biotechnology, Inc.:

The EPS of VIRis strolling at -5.76, measuring its EPS growth this year at -443.3%. As a result, the company has an EPS growth of 3.3% for the approaching year.

Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We cant have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.

Analysts mean target price for the company is $33.33 while analysts mean suggestion is 3.2.

A beta factor is used to measure the volatility of the stock. The stock remained 14.54% volatile for the week and 22.72% for the month.

Historical Performance In The News:

Taking a look at the performance of Vir Biotechnology, Inc.stock, an investor will come to know that the weekly performance for this stock is valued at 3.38%, resulting in a performance for the month at -19.69%.

Therefore, the stated figure displays a quarterly performance of 201.07%, bringing six-month performance to 0% and year to date performance of 191.85%.

P/S, P/E, P/C and P/B/ SMA50, SMA 200:

The price-to-sales is a valuation ratio that relates a companys stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a companys sales or taxes. As of now, VIR has a P/S, P/E and P/B values of 501.93, 0 and 1.16 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.

Its P/Cash valued at 10.6. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stocks price to its cash flow per share

What do you mean by simple moving average (SMA)?

A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is -0.26%, and its distance from 50 days simple moving average is 19.04% while it has a distance of 77.29% from the 200 days simple moving average. The companys distance from 52-week high price is 264% and while the current price is 264% from 52-week low price.

Read the original:
Data Shows Recession Fears May Be Overblown:: Vir Biotechnology, Inc., (NASDAQ: VIR) - NasdaqNewsFeed

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Continue reading here:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

Today, well introduce the concept of the P/E ratio for those who are learning about investing. Well show how you can use Apex Biotechnology Corp.s (TPE:1733) P/E ratio to inform your assessment of the investment opportunity. Apex Biotechnology has a P/E ratio of 19.61, based on the last twelve months. That is equivalent to an earnings yield of about 5.1%.

Check out our latest analysis for Apex Biotechnology

The formula for P/E is:

Price to Earnings Ratio = Price per Share Earnings per Share (EPS)

Or for Apex Biotechnology:

P/E of 19.61 = NT$22.350 NT$1.140 (Based on the trailing twelve months to December 2019.)

(Note: the above calculation results may not be precise due to rounding.)

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. All else being equal, its better to pay a low price but as Warren Buffett said, Its far better to buy a wonderful company at a fair price than a fair company at a wonderful price.

The P/E ratio indicates whether the market has higher or lower expectations of a company. As you can see below Apex Biotechnology has a P/E ratio that is fairly close for the average for the medical equipment industry, which is 18.3.

Its P/E ratio suggests that Apex Biotechnology shareholders think that in the future it will perform about the same as other companies in its industry classification. So if Apex Biotechnology actually outperforms its peers going forward, that should be a positive for the share price. Further research into factors such as insider buying and selling, could help you form your own view on whether that is likely.

Earnings growth rates have a big influence on P/E ratios. Thats because companies that grow earnings per share quickly will rapidly increase the E in the equation. And in that case, the P/E ratio itself will drop rather quickly. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

Apex Biotechnology increased earnings per share by an impressive 19% over the last twelve months. And earnings per share have improved by 229% annually, over the last three years. So one might expect an above average P/E ratio. Unfortunately, earnings per share are down 16% a year, over 5 years.

The Price in P/E reflects the market capitalization of the company. So it wont reflect the advantage of cash, or disadvantage of debt. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

The extra options and safety that comes with Apex Biotechnologys NT$214m net cash position means that it deserves a higher P/E than it would if it had a lot of net debt.

Apex Biotechnology trades on a P/E ratio of 19.6, which is above its market average of 14.1. Its net cash position supports a higher P/E ratio, as does its solid recent earnings growth. So it does not seem strange that the P/E is above average.

Investors should be looking to buy stocks that the market is wrong about. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
Heres What Apex Biotechnology Corp.s (TPE:1733) P/E Is Telling Us - Simply Wall St

CHICAGO, April 2, 2020 /PRNewswire/ --ARCH Venture Partnerstoday announced the closing of two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, with a combined $1.46 billion to invest in transformative, early stage biotechnology companies.

ARCH Venture Partners Logo

"ARCH has always been driven to invest in great science to impact human health. There isn't a better illustration of our principles than our all-in battle against COVID-19. The healthcare revolution will be accelerated by the changes that are happening now and we are excited to continue to invest aggressively in risk takers doing truly transformational science," said co-founder and Managing Director Robert Nelsen.

ARCH will deploy Fund X and Fund X Overage to invest in early stage companies. While ARCH will frequently co-invest in a company with both funds, Fund X Overage will be utilized in fewer deals requiring larger investments. Limited partners include endowments, family offices, sovereign wealth funds and other institutional investors.

"Our companies bring cutting-edge science, tools and talent to bear in developing medicines for a wide range of diseases and conditions faced by millions. With these two new funds, we are continuing that work with urgency and a deep sense of purpose. We invest at all levels, whether it's fifty thousand dollars or hundreds of millions, so that each company and each technology has the best chance to advance and change the landscape," said Managing Director Kristina Burow.

Fund X and Fund X Overage follow ARCH Venture Fund IX and ARCH Venture Fund IX Overage, which closed in 2016 with a combined $1.1 billion. ARCH Venture Fund VIII and ARCH Venture Fund VIII Overage closed in 2014 with a combined $560 million.

"ARCH remains committed to our mission of the last 35 years, advancing the most promising innovations from leading life science and physical sciences research to serve the worldwide community by addressing critical health and well-being challenges. ARCH has been privileged to found, support and invest in groundbreaking new companies pursuing advancements in infectious disease, mental health, immunology, genomic and biological tools, data sciences and ways of reimagining diagnostics and therapies," said co-founder and Managing Director Keith Crandell.

Early stage ARCH investments have included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Brii Biosciences, Twist Biosciences, Aviron, Ikaria, Gossamer Bio, Fate Therapeutics, Array Biopharma, Adolor, Quanterix, 908 Devices, Unity Biotechnology, Hua Medicine, deCODE Genetics, Homology Medicines and others.

In the battle against COVID-19, ARCH companies Vir Biotechnology, Alnylam Pharmaceuticals, VBI Vaccines, Brii Biosciences and Sana Biotechnology are currently working to develop COVID-19 therapeutics; Quanterix is advancing technology that can help with clinical testing needs and support clinical trial continuity; Twist Biosciences is advancing genomic and gene engineering tools used in COVID-19 therapeutic and vaccine development; and Bellerophon's inhaled nitric oxide (iNO) delivery system recently received emergency expanded access approval from the Food and Drug Administration for treatment of COVID-19.

Story continues

"ARCH is still willing to sit down with a scientist with a lab notebook to develop and translate great science into great companies. Fundamental science is what drives us and creating new diagnostics and disease modifying and curative therapies is what motivates us," said Managing Director Steve Gillis.

ARCH's Managing Directors include:

About ARCH Venture Partners:

ARCH Venture Partners invests in advanced technology companies and is one of the largest early stage technology venture firms in the United States. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

For more information, visit http://www.archventure.com.

Contact:Morgan Warnersmwarners@gpg.com 202-337-0808

View original content to download multimedia:http://www.prnewswire.com/news-releases/arch-venture-partners-announces-1-46-billion-raised-in-two-new-funds-to-invest-in-transformative-biotechnology-companies-301033707.html

SOURCE ARCH Venture Partners

View original post here:
ARCH Venture Partners Announces $1.46 Billion Raised in Two New Funds to Invest in Transformative Biotechnology Companies - Yahoo Finance

The Marine Biotechnology market report provides a detailed analysis of this business space. The market is analyzed in terms of production as well as consumption. Based on the production aspect, the report includes particulars pertaining to the manufacturing processes of the product, alongside revenue and gross margins of the respective manufacturers. The unit cost decided by the producers across various regions during the forecast period is also included in the report.

Additionally, the study comprises of insights regarding the consumption pattern. Information concerning the product consumption volume and product consumption value is mentioned in the document. The individual sale price along with the status of the export and import graphs across various regions are provided. Meanwhile, an in-depth analysis of the production and consumption patterns during the estimated timeframe has been given.

A summary of the geographical landscape:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/36827

An overview of the product landscape:

An outline of the application spectrum:

A gist of the competitive landscape:

In a nutshell, the Marine Biotechnology market report encompasses details about the equipment, downstream buyers and upstream raw materials. Growth factors impacting this industry vertical in consort with the marketing strategies implemented by the manufacturers have been analyzed and provided in the research report. The Marine Biotechnology market study report also offers insights regarding the feasibility of new investment projects.

Report Objectives:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/36827

Continued here:
Outlook on the Marine Biotechnology Market to 2024 by Application, End-user and Geography - Express Journal

A rating of 64 puts Sarepta Therapeutics Inc (SRPT) near the middle of the Biotechnology industry according to InvestorsObserver. Sarepta Therapeutics Inc's score of 64 means it scores higher than 64% of stocks in the industry. Sarepta Therapeutics Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 11 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sarepta Therapeutics Inc (SRPT) stock is trading at $167.62 as of 11:39 AM on Friday, Jun 19, an increase of $2.40, or 1.45% from the previous closing price of $165.22. The stock has traded between $165.74 and $168.85 so far today. Volume today is low. So far 200,391 shares have traded compared to average volume of 1,087,373 shares.

To see the top 5 stocks in Biotechnology click here.

Continued here:
Is Sarepta Therapeutics Inc (SRPT) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Investors might want to bet on PDS Biotechnology (PDSB), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for PDS Biotechnology basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for PDS Biotechnology imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate Revisions

As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for PDS Biotechnology

This biotechnology company is expected to earn -$2.33 per share for the fiscal year ending December 2020, which represents a year-over-year change of 34.7%.

Analysts have been steadily raising their estimates for PDS Biotechnology. Over the past three months, the Zacks Consensus Estimate for the company has increased 15%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of PDS Biotechnology to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEdge Therapeutics, Inc. (PDSB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

The rest is here:
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

The White Biotechnology market growth prospects have been showing good great promise all over the world with immense growth potential in terms of revenue generation and this growth of the White Biotechnology market is expected to be huge by 2026.The growth of the market is driven by key factors such as manufacturing activity in accordance with the current market situation and demand that seems to be seeing a major upward trend in some time, risks of the market, acquisitions, new trends, assessment of the new technologies and their implementation.

Top Companies covering This Report:- Novozymes, Kaneka Corporation, Biosphere, Angel Yeast Co. Ltd., Genecor, DSM, Akzo Nobel, BASF SE, Henkel AG., Du Pont Danisco.

This report has been detailed and is structured in a manner that covers all of the aspects required to gain a complete understanding of the pre-market conditions, current conditions as well as a well-measured forecast in order for the client to establish a strong position in the White Biotechnology market.

The report has been segmented and discussed in detail with the consideration of the COVID-19 situation, and is as per the examined essential aspects such as sales, revenue, market size, and other aspects that are crucial to post good growth numbers in the market and emerge as a leader in the market.

Get Sample PDF Brochure@ https://www.reportsintellect.com/sample-request/633834

Get this report now @ https://www.reportsintellect.com/buynow/633834

Description:

In this report, we are providing our readers with the most updated data on the White Biotechnology market and as the international markets have been changing very rapidly over the past few years the markets have gotten tougher to get a grasp of and hence our analysts have prepared a detailed report while taking in consideration the history of the market and a very detailed forecast along with the market issues and their solution.

The given report has focused on the key aspects of the markets to ensure maximum benefit and growth potential for our readers and our extensive analysis of the market will help them achieve this much more efficiently. The report has been prepared by using primary as well as secondary analysis in accordance with porters five force analysis which has been a game-changer for many in the White Biotechnology market. The research sources and tools that we use are highly reliable and trustworthy. The report offers effective guidelines and recommendations for players to secure a position of strength in the White Biotechnology market. The newly arrived players in the market can up their growth potential by a great amount and also the current dominators of the market can keep up their dominance for a longer time by the use of our report.

White Biotechnology Market Type Coverage:

BiofuelBiochemicalBiopolymers

White Biotechnology Market Application Coverage:

BioenergyFood and Feed AdditivesPharmaceutical IngredientsPersonal Care and Household ProductsOther Fine Chemicals

Market Segment by Regions, regional analysis covers

North America (United States, Canada, Mexico)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Europe, Middle East and Africa (Germany, France, UK, Russia and Italy, Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/633834

Competition analysis

As the markets have been advancing the competition has increased by manifold and this has completely changed the way the competition is perceived and dealt with and in our report, we have discussed the complete analysis of the competition and how the big players in the White Biotechnology market have been adapting to new techniques and what are the problems that they are facing.

Our report which includes the detailed description of mergers and acquisitions will help you to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Why us:

Reasons to buy:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.comPhone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Link:
New Report on the White Biotechnology Market (Covid-19 Updated) explores the latest trends and a details a forecast till 2026 | DSM, Akzo Nobel, BASF...

New Jersey, United States,- A detailed research study on Nanoparticles in Biotechnology and Pharmaceuticals Market recently published by Verified Market Research. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Nanoparticles in Biotechnology and Pharmaceuticals, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Leading Nanoparticles in Biotechnology and Pharmaceuticals manufacturers/companies operating at both regional and global levels:

Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Nanoparticles in Biotechnology and Pharmaceuticals market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=003

Nanoparticles in Biotechnology and Pharmaceuticals Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Nanoparticles in Biotechnology and Pharmaceuticals market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Nanomagnetic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Naphthalene Water Reducers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Go here to read the rest:
Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Trends, Top Manufacturers, Growth, Statistics, Opportunities and Forecast To 2026...

CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Childrens Hospital.

We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology, said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.

Many years in academia, biotechnology and pharma have given me the experience and perspective to recognize the importance of Dr. Hes discovery and what AXONIS is aiming to achieve, said Corey Goodman, PhD, Executive Chair and co-founder of AXONIS. That background underscores my excitement in AXONIS neuromodulating therapy not only for spinal cord injury, the initial focus, but also other neurological disorders, such as epilepsy, where it also has major potential.

The second tranche of the financing will be provided following the Companys successful delivery of proof-of-concept data, which is expected in approximately one year. The financing follows the strengthening of the leadership team including the appointment of Dr. Stanicka as CEO in October 2019, along with an expanded Board of Directors. Under the new leadership, AXONIS received state and federal non-dilutive funding and other seed investment. Dr. Stanicka also won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral in Cambridge.

AXONIS has licensed or optioned two technologies from Boston Childrens Hospital, the leading pediatric hospital in the world. In addition to its primary work on the KCC2 protein, AXONIS has also been investigating PTEN inhibition to help regenerate nerve connections after injury. Through tissue reactivation and nerve regeneration, AXONIS is focused on identifying effective therapies to restore movement in paralyzed patients after spinal cord injury.

Spinal cord injury causes devastating paralysis, loss of sensation and loss of other bodily functions below the level of the injury. Across the US, Canada and Western Europe, it is estimated that there are more than 3.6 million cases, and more than 180,000 new cases each year, with each SCI patient requiring more than $100,000, on average, in annual care.

AXONIS Science Advisory Council includes Oswald Steward, PhD, Director of the Reeve-Irvine Research Center at the University of California at Irvine; Lisa McKerracher, PhD, CEO, BioAxone BioSciences, Inc.; and Dr. Goodman, Managing Partner, venBio Partners.

AXONIS was founded by Bob Yant, a well-known advocate for spinal cord regeneration research. Following a 1981 accident that left Bob a quadriplegic, he has dedicated significant time to raising funds for basic research aimed at developing a cure for spinal cord injury. Bob is a former Director of the Christopher and Dana Reeve Foundation, and Founder of Cure Medical.

About AXONIS Therapeutics

AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders. AXONIS is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and PTEN inhibition to regenerate injured nerve connections, to make a real difference for patients, their families, and the global healthcare system. For more information, visit http://www.axonis.us

The rest is here:
AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy - Business Wire

GENERAL

Green Vision Biotechnology Corp. (the "Company"), formerly known as VibeWireless Corp., also formerly known as Any Translation Corp., was incorporatedunder the laws of the State of Nevada on July 5, 2012. We were founded to be inthe business of translation and interpretation. The Company undertooktranslation and interpretation projects for various fields from business,economics, to science issues. The Company later adopted a business plan topursue business opportunities in the global telecommunications industry.

On September 2, 2015, a change in control of the Company took place by virtue ofthe Company's largest shareholder and sole officer and director at that time,selling 4,000,000 shares of the Company's common stock to Forestbay CapitalPartners II, LLC, a Delaware limited liability company. Such shares represented65.8% of the Company's total issued and outstanding shares of common stock. Aspart of the sale of the shares, Forestbay Capital Partners arranged with theformer officer and director, prior to his resignation as the sole officer anddirector of the Company Board, to appoint Mr. Edward Mooney as the sole officerand director of the Company. Mr. Mooney is the Manager of Forestbay CapitalPartners II, LLC.

On November 12, 2015, we changed our name to Vibe Wireless Corp in connectionwith merging with our wholly-owned subsidiary. This name change and our tickersymbol change was acknowledged by FINRA and effected in the market on November23, 2015.

The Company was originally incorporated under the laws of the State of Nevada onJuly 5, 2012 as Any Translation Corp.

On September 30, 2016, the Company filed a Certificate of Amendment with theNevada Secretary of State (the "Nevada SOS") whereby it amended its Articles ofIncorporation to increase the Company's authorized number of shares of commonstock from 75 million to 750 million and forward split all of its issued andoutstanding shares of common stock at a ratio of ten (10) shares for every one(1) share held. The Company's Board of Directors approved this amendment onSeptember 30, 2016.

On September 30, 2016, the Company filed Articles of Merger with the Nevada SOSwhereby it entered into a statutory merger with its wholly-owned subsidiary,Green Vision Biotechnology Corp. pursuant to Nevada Revised Statutes 92A.200 et.seq. The effect of such merger is that the Company is the surviving entity andchanged its name to "Green Vision Biotechnology Corp."

On September 30, 2016, the Company filed an Issuer Company-Related ActionNotification Form with FINRA requesting that the aforementioned forward splitand name change be effected in the market. The Company also requested that itsticker symbol be changed to "GVBT". This name change and our ticker symbolchange was acknowledged by FINRA and effected in the market on November 27,2016.

As disclosed in our Current Report on Form 8-K dated May 12, 2017 there was achange in our management. Effective May 3, 2017, the Company accepted theresignation of Edward P. Mooney as the sole officer of the Company and as thesole member of the Company's board of directors. Simultaneously, Mr. Ma Wai Kin,was elected as the Company's President, Secretary, Treasurer and a member of theBoard of Directors.

Our financial statements have been prepared assuming that we will continue as agoing concern and, accordingly, do not include adjustments relating to therecoverability and realization of assets and classification of liabilities thatmight be necessary should we be unable to continue our operation.

We expect we will require additional capital to meet our long-term operatingrequirements. We expect to raise additional capital through, among other things,the sale of equity or debt securities.

Result of Operations for the Three months ended March 31, 2019 and 2018

Revenue was $29,834 for the three months ended March 31, 2019 ("Q1"), decreasedby $23,083, or 43.6% from $52,917 for the three months ended March 31, 2018("Comparable Quarter"). The decrease in revenue during the Q1 as compared to theComparable Quarter was due to the restrictions on our production capacity as aresult of the enforcement on new environmental regulations over industrialproduction by coal-fired boilers by local authorities in Shanxi. In thisquarter, our company has conducted various field trials in Guangxi,Heilongjiang, and Yunnan in order to promote our products.

Cost of sales was decreased by $8,245, or 22.1% from $37,255 in the ComparableQuarter to $29,010 in Q1. The decrease was due to the decrease in productioncorresponding to the decrease in the sales revenue. In terms of percentage ofrevenue, cost of sales was 97.2% in Q1 as compared to 70.4% in the ComparableQuarter. The decrease in cost of sales with the increase in percentage torevenue, was due to the significant decrease in the production level whichworsen the mass of production effect.

Gross profit was decreased by $14,838, or 94.7% from $15,662 in the ComparableQuarter to $824 in Q1. The decrease reflected the correlation in reduction ofrevenue. In terms of percentage of revenue, the gross profit percentage wasdecreased to 2.8% for Q1 as compared to 29.6% for the Comparable Quarter. Thedecrease was primarily due to the significant drop in the sales revenue withresulted to the decrease in the production level.

Selling expenses were decreased by $3,851 or 98.8% from $3,898 for theComparable Quarter to $47 in Q1. In terms of percentage of revenue, the rateswere 0.2% in Q1 compared to 7.4% in the Comparable Quarter. The decrease isprimarily due to the decrease of testing expenses and shipping andtransportation expenses which were correlated to the decrease in sales.

General and administrative expenses were decreased by $144,405, or 59.3% from$243,371 for the Comparable Quarter to $98,966 for Q1. The decrease is primarilydue to the salary and consultation fee in Q1.

The following is a summary of general and administrative expenses for the threemonths ended March 31, 2019, and 2018.

Salary and payroll expenses 15,507 54,832 (39,325 )Professional fees

Consulting fees were decreased by $42,977, or 73.4%, from $58,585 in ComparableQuarter to $15,608 in Q1, owing to the engagement of less external consultantsto improve the Company's operating activities in the Comparable Quarter.

Our salary and payroll expenses were decreased by $39,325, or 71.7%, to $15,507in Q1, as compared to $54,832 in the Comparable Quarter. We anticipate thatsalary and payroll expenses will rise in future periods as it becomes necessaryto increase our staff in order to enhance our management quality for the listingrequirement and to increase our production activities.

Professional fees were decreased by $501, from $7,909 in Comparable Quarter to$7,408 in Q1. The decrease of professional fees was due to the engagement ofless independent professionals such as international lawyers and accountants.

Travel and entertainment expenses were decreased by $11,404, or 55.0%, from$20,735 in Comparable Quarter to $9,331 in Q1. The decrease of travel andentertainment expenses was due to the reduction of project-based travellingactivities.

Research and Development expenses were decreased to $Nil in Q1 from $786 inComparable Quarter.

Depreciation and amortization expenses were decreased by $12,750, or 23.0%, from$55,428 in Comparable Quarter to $42,678 in Q1.

Other expenses include items such as office expenses, software related costs,telephone and a variety of other miscellaneous expenses. None of these expensesalone changed significantly except transportation fee, as the difference was$36,662, or 81.3% decrease from $45,096 in Comparable Quarter to $8,434 in Q1.

We anticipate that we will incur higher general and administrative expenses as apublic company. We expect that our professional fees, cost of transfer agent,investor relations costs and other stock related costs will increase.

We also anticipate that selling, general and administrative expenses willconcurrently increase with our increased activity in the future but will notincrease in the same proportion to that of revenue.

Our loss from operations was decreased by $133,418 or 57.6%, to negative $98,189in Q1, from $231,607 in Comparable Quarter.

Non-operating income (expenses) was increased by $24,201, or 1419%, to income of$22,495 in Q1, from expenses of negative $1,706 in Comparable Quarter, of whichmainly due to the increase of other income increase $28,135 from $124 inComparable Quarter to $28,259 in Q1.

The net loss attributed to the Company was reduced by $157,619, or 67.6% tonegative $75,694 in Q1, as compared to negative $233,313 in Comparable Quarter.

Liquidity and Capital Resources

The Company's liquidity and capital is dependent on whether the Company iscapable of generating its revenues and increasing its capital for thedevelopment and expansion of its business.

Management plans to support the Company's operation and its business strategy byraising funds through public and private offerings and relying on officers anddirectors to perform essential management functions with minimal compensation.If we do not raise all of the money we need from a public offering, we will haveto find alternative sources, such as a private placement of securities, or loansfrom our officers, directors or others. The loans are likely to be unsecured,non-interest bearing and repayable at demand.

Moreover, management has actively taken steps to revise its operating andfinancial needs. Management believes that the Company's current and availablecapital resources will allow it to continue its operations throughout thisfiscal year.

At March 31, 2019, we had a working capital deficit of $9,718,626, as comparedto a working capital deficit of $9,596,914 at December 31, 2018. Of the workingcapital deficit at March 31, 2019, $9,454,171 was amount due to related partiesand shareholder. Excluding the amounts due to related parties and shareholder,we would have had a negative working capital of $264,455 at March 31, 2019. Ascomparison, the working capital deficit at December 31, 2018, $9,361,322 wasamount due to related parties and holding company. Excluding the amounts due torelated parties and holding company, we would have had a negative workingcapital of $235,592 at December 31, 2018. The amounts due to related parties andshareholder are unsecured, interest free and repayable on demand.

During the three months ended March 31, 2019, operating activities used cash of$4,550, and for the comparable three months ended March 31, 2018, operatingactivities used cash in operations of $122,676. The use of cash in operatingactivities for the three months ended March 31, 2019 was mainly derived from anet loss of $75,694 with a non-cash item of $42,678 ($36,710 plus $5,968) indepreciation and amortization and negative $66,640 in inventory provisionreversal ; moreover, there was an increase in cash of $66,640 in inventories; anincrease in cash of $38,113 in other payable and an increase in cash of $21,813in accrued expenses, which were offset by a decrease in cash of $1,883 inaccounts receivable; a decrease in cash of 2,402 in accounts payable; a decreasein cash of $25,084 in accrued payroll and a decrease in cash of $2,509 in amountdue to related parties. As comparison, the use of cash in operating activitiesfor the comparable three months ended March 31, 2018 was mainly derived from anet loss of $ $233,313 with a non-cash item of $67,498 ($61,167 plus $6,331) indepreciation and amortization; moreover, there was an increase in cash of$10,230 in inventories; an increase in cash of $13,843 in other receivables; anincrease in cash of $26,664 in other payable and an increase in cash of $55,215in amount due to related parties, which were offset by a decrease in cash of$33,882 in accounts receivable; a decrease in cash of 10,613 in tax payables;and a decrease in cash of $34,942 in accrued expenses.

During the three months ended March 31, 2019, investing activities used $Nil ofcash; and for comparable three months ended March 31, 2018, investing activitiesused $2,112 of cash.

During the three months ended March 31, 2019, financing activities provided cashof $8,730; and for comparable three months ended March 31, 2018, financingactivities provided cash of $104,692. The change of cash provided by financingactivities was derived from the changes in the amounts due to our shareholder.

As at March 31, 2019, net cash and cash equivalents balance was $13,447 ascompared to balance $9,114 as at December 31, 2018.

As of March 31, 2019, stockholder's equity was negative $6,489,388, compared toa negative equity of $6,405,098 at December 31, 2018.

The source of fund for supporting the Company's business operation was loansfrom directors and shareholders. In the event the directors and shareholders donot continue to support the Company's business operation, the Company could beshort of funds and may not be able to operate any longer. The amounts due torelated parties and director are interest-free loans. These loans are unsecuredand have no fixed repayment terms.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through acombination of our existing funds, loans from third parties, other debtfacilities, or further issuances of securities. Our working capital requirementsare expected to increase in line with the growth of our business.

Existing working capital, further advances and debt instruments, and anticipatedcash flow are expected to fund our operations over the next three months. Wehave no lines of credit or other bank financing arrangements. In connection withour business plan, management anticipates additional increases in operatingexpenses and capital expenditures relating to: (i) developmental expensesassociated with a growing business; and (ii) marketing expenses. We intend tofinance these expenses with further issuances of securities, and debt issuances.Thereafter, we expect we will need to raise additional capital and generaterevenues to meet long-term operating requirements. Additional issuances ofequity or convertible debt securities will result in dilution to theshareholdings of our current shareholders. Further, such securities might haverights, preferences or privileges senior to our common stock. Additionalfinancing may not be available upon acceptable terms, or at all. If adequatefunds are not available or are not available on acceptable terms, we may not beable to take advantage of prospective new business endeavors or opportunities,which could significantly and materially restrict our business operations. Wewill have to raise additional funds in the next twelve months in order tosustain and expand our operations. We currently do not have a specific plan ofhow we will obtain such funding; however, we anticipate that additional fundingwill be in the form of equity financing from the sale of our common stock. Wehave and will continue to seek to obtain short-term loans from our directors,although no future arrangement for additional loans has been made. We do nothave any agreements with our directors concerning these loans. We do not haveany arrangements in place for any future equity financing.

Since 2017, local government of Jinzhong City, Shanxi Province, China (whereShanxi Lutu and our production plant is located) has promulgated a new set ofenvironmental regulations restricting the use of coal-fired boilers infactories. Since coal-powered generators were used in our production plant, ourproduction activities in 2019 were restricted to a certain extent.

We cannot ensure that we can comply with the new environmental regulations intime. If that is the case, our production and our production capacity may bereduced as a result. This will affect our ability to generate income and to meetthe demand of our customers, which in turn could have a material adverse effecton our financial condition and results of operations.

Due to the enforcement on new environmental regulations over industrialproduction by coal-fired boilers by local authorities in Shanxi, the Company'sproduction was restricted to a certain extent in 2017. In order to fully complywith the new environmental regulations in place, management of the Company hadplanned to carry our rectification work and expected that the rectification workcould be completed by mid of 2018 and full-scale production might resume in thesecond half of 2018. However, due to the shortage of funding to carry out therectification work on our coal-powered generators, our production activitieswere restricted since second quarter in 2018. Our production and our productioncapacity was reduced as a result, significantly affected our ability to generateincome and to meet the demand of our customers, which in turn had a materialadverse effect on our financial condition and results of operations. Themanagement had decided to maintain our business by way of sub-contracting orassignment of the production. Furthermore, the management had further researchedfor other business opportunity to utilize the reduced capacity of the propertyand equipment, in order to make better the worsened revenue.

Off-Balance Sheet Arrangements

As of the date of this Quarterly Report, we do not have any off-balance sheetarrangements that have or are reasonably likely to have a current or futureeffect on our financial condition, changes in financial condition, revenues orexpenses, results of operations, liquidity, capital expenditures or capitalresources that are material to investors.

The independent auditors' report accompanying our December 31, 2018 auditedfinancial statements filed in Form 10-K on May 15, 2020 contained an explanatoryparagraph expressing substantial doubt about our ability to continue as a goingconcern. The financial statements have been prepared "assuming that we willcontinue as a going concern," which contemplates that we will realize our assetsand satisfy our liabilities and commitments in the ordinary course of business.

Edgar Online, source Glimpses

Excerpt from:
GREEN VISION BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - marketscreener.com

Dublin, May 07, 2020 (GLOBE NEWSWIRE) -- The "Androstadienedione Market Insights 2020 - Analysis and Forecasts for the Global and Chinese Markets to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

This report is a professional and in-depth study on the current state of the global Androstadienedione market with a focus on the Chinese market. The report provides key statistics on the market of Androstadienedione. It is a valuable source of guidance and direction for companies and individuals interested in Androstadienedione industry.

Key points

Key Topics Covered:

1. Introduction of Androstadienedione Industry1.1 Brief Introduction of Androstadienedione1.2 Development of Androstadienedione Industry1.3 Status of Androstadienedione Industry

2. Manufacturing Technology of Androstadienedione2.1 Development of Androstadienedione Manufacturing Technology2.2 Analysis of Androstadienedione Manufacturing Technology2.3 Trends of Androstadienedione Manufacturing Technology

3. Analysis of Global Key Manufacturers 3.1 Hubei Goto Biopharm3.1.1 Company Profile3.1.2 Product Information3.1.3 Capacity Production Price Cost Production Value3.1.4 Contact Information3.2 Shandong Sito Biotechnology3.2.1 Company Profile3.2.2 Product Information3.2.3 Capacity Production Price Cost Production Value3.2.4 Contact Information

4. 2015-2020 Global and Chinese Market of Androstadienedione4.1 Market Size4.1.1 2015-2020 Global Capacity, Production and Production Value of Androstadienedione Industry4.1.2 2015-2020 Chinese Capacity, Production and Production Value of Androstadienedione Industry4.2 2015-2020 Androstadienedione Industry Cost and Profit Estimation4.3 Market Comparison of Global and Chinese Androstadienedione Industry4.4 2015-2020 Global and Chinese Supply and Consumption of Androstadienedione4.5 2015-2020 Import and Export of Androstadienedione

5. Market Status of Androstadienedione Industry5.1 Market Competition of Androstadienedione Industry by Company5.2 Market Competition of Androstadienedione Industry by Region5.3 Market Analysis of Androstadienedione Industry by Application5.4 Market Analysis of Androstadienedione Industry by Type

6. Market Forecast of 2020-2025 Global and Chinese Androstadienedione Industry6.1 2020-2025 Global and Chinese Capacity, Production, and Production Value of Androstadienedione6.2 2020-2025 Androstadienedione Industry Cost and Profit Estimation6.3 2020-2025 Global and Chinese Market Share of Androstadienedione6.4 2020-2025 Global and Chinese Supply and Consumption of Androstadienedione6.5 2020-2025 Import and Export of Androstadienedione

7. Analysis of Androstadienedione Industry Chain7.1 Industry Chain Structure7.2 Upstream Raw Materials7.3 Downstream Industry

8. Global and Chinese Economic Impact on Androstadienedione Industry8.1 Global and Chinese Macroeconomic Environment Analysis8.2 Global and Chinese Macroeconomic Environment Development Trend8.3 Effects to Androstadienedione Industry

9. Market Dynamics and Policy of Androstadienedione Industry9.1 Androstadienedione Industry News9.2 Androstadienedione Industry Development Challenges9.3 Androstadienedione Industry Development Opportunities9.4 Androstadienedione Industry Development Opportunities

10. Proposals for New Project10.1 Market Entry Strategies10.2 Countermeasures of Economic Impact10.3 Marketing Channels10.4 Feasibility Studies of New Project Investment

11. Research Conclusions of Global and Chinese Androstadienedione Industry

For more information about this report visit https://www.researchandmarkets.com/r/1f6s4r

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more here:
Insights on the Worldwide Androstadienedione Industry to 2025 - Featuring Hubei Goto Biopharm and Shandong Sito Biotechnology - GlobeNewswire

The fight against the coronavirus is being waged in science labs right in our backyard. Scientists with the nonprofit Baruch S. Blumberg Institute, which manages the Pennsylvania Biotechnology Center community, are conducting antibodies tests in area hospitals and working on a drug candidate that shows promise for treating COVID-19.

Inside a lab in Pennsylvania Biotechnology Center, Dr. Patrick Romano held out a tray of vials, each containing serum extracted from patients and hospital employees who have recovered from COVID-19.

We are one of the first companies in the local area to be doing antibody testing against the SARS-COVID-19. We are working with local health care professionals to provide this data to help them screen their employees, said Romano, a research and innovation specialist with FlowMetric Diagnostics and a Baruch S. Blumberg Institute professor who is looking for antibodies against the COVID-19 virus.

Romano is among dozens of scientists from seven companies in the nonprofit research center who are battling the deadly virus on many fronts. FlowMetric and Serologix are working to meet the urgent demands of hospitals seeking diagnostic tests to determine if people have been exposed to COVID-19 and if they have developed antibodies.

Romano said he hopes to soon work with area hospitals to identify patients who would be candidates for convalescent serum donations, which he said is a critical need for people who are critically ill right now. Convalescent plasma is being investigated across the globe for the treatment of COVID-19 because there is research gained from previous scientific studies suggesting it might help individuals recover.

Earlier this week, Bucks County health and government officials reached out to the Biotechnology Center to discuss expanding antibodies testing capabilities.

Thousands of tests have been done here, said Timothy Block, president of both the institute and the biotechnology center, which is home to 55 biotech companies. He added that Blumberg scientists are not just working behind the scenes.

They are actively involved in fighting the crisis right now, said Block. They are responding to wherever hospitals locally are asking for help.

Responding to immediate needs to expand capacity for testing in area hospitals has been a big priority. So has researching and developing treatments.

Inside the Pennsylvania Biotechnology Center community, managed by the nonprofit Blumberg Institute on Old Easton Road in Buckingham, scientists are conducting research with a drug candidate they developed years ago to determine if it could be an effective treatment for COVID-19.

We have been working on antiviral drugs for two decades at Blumberg, said Block, founder of the virology research center and the Hepatitis B Foundation. Our focus has been hepatitis B, liver cancer and other cancers, but some of the drugs we have discovered appear to have activity against other viruses.

The nonprofit research engine of the biotechnology center, the Blumberg Institute, said two promising approaches are being developed by Bixi Life Sciences, based at the center.

For one of those projects, Iminovirs, scientists are investigating a family of drugs, called iminosugar ER glucosidase inhibitors, which significantly reduce the replication of SARS-1 (the cause of SARS). Based on how it works, it may have activity against SARS-CoV-2.

In the lab of Dr. Yizeng Yang, scientists are synthesizing mini-antibody mimetics, intended to prevent SARS-CoV 2 from binding to and attacking target cells. These would serve as artificial antibodies.

A live virus is not being used for testing at the center, and scientists are working with partnering institutions to develop their research, Block said.

We dont have the ability to test it against the actual authentic virus here, said Block, who said the project is being tested at the University of Pennsylvania Perelman School of Medicine. We are a little ways away from knowing whether the drug will have activity against the cause of COVID-19. But we are looking into our toolkit to see what we have.

While there is no way of predicting whether a cure for COVID-19 will stem from the research, Block said hes proud of scientists dedication in finding a way to fight the pandemic.

Right in our back yard, here is this busy center where scientists are rising to the occasion doing what they can, carrying out tests for COVID-19 and where research is being done for our future.

To develop that toolkit, funding the work is essential, said Lou Kassa, executive vice president and chief operating officer for the institute and the biotech center.

To foster support, the center has created a Covid-19 Blumberg Action Fund, which would help the Blumberg Institutes efforts to repurpose existing drugs and methods for the treatment and control of COVID-19.

Read the original here:
Doylestown Biotechnology center, Blumberg Institute, on the front lines of coronavirus fight - The Intelligencer